Soluble B7-H3 as a Biomarker for Osteosarcoma

Peking University

Status: Enrolling

Conditions: Osteosarcoma; Surveillance; Biomarker; Progression

Treatments: Diagnostic Test: ELISA: enzyme-linked immunosorbent assay

Study type: Observational

Funder types: Other

Identifiers

NCT05942456

PKUPH-sarcoma 16

Details and patient eligibility

About

Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies. However, the level of sB7-H3 and its clinical significance in osteosarcoma are not well known. In this present study, we investigated whether sB7-H3 levels in serum could be as a biomarker for osteosarcoma treatment.

Enrollment: 200 estimated patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• High Grade osteosarcoma verified with pathologic diagnosis.
• systemic treatment-naive before the first time Blood drawing.
• ECOG 0 or 1 and all the other imagings indicate that patients could tolerate standard PKUPH-OS-02 protocol neoadjuvant chemotherapy.
• All radiographs are complete for clinical evaluation.

Exclusion criteria

• Patients who Can't tolerate blood drawing.
• Patients without complete medical records in PKUPH system.
• Patients who can't tolerate PKUPH-OS-02 neoadjuvant chemotherapy.
• other conditions that investigators think are not suitable for this study.

Trial design

200 participants in 2 patient groups

sB7-H3 of treatment-naive osteosarcoma patients

Description:

Before delivering neoadjuvant chemotherapy, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood

Treatment:

Diagnostic Test: ELISA: enzyme-linked immunosorbent assay

sB7-H3 after neoadjuvant chemotherapy for osteosarcoma patients

Description:

After neoadjuvant chemotherapy and before definitive surgery, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood

Treatment:

Diagnostic Test: ELISA: enzyme-linked immunosorbent assay